Fig. 2From: The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective studyKaplan–Meier analysis of progression-free survival (left panels) and overall survival (right panels). Kaplan–Meier estimates of survivals according to the incidence of sunitinib-related hypertension (a, b), serum level of CRP (c, d) and sodium (e, f) at baseline. The time to the events is given in monthsBack to article page